The $35 million BioMedTech Horizons (BMTH) programme is inviting expressions of interest (EOI), with grants of up to $1 million of funding available over a two-year period. Expressions of interest should address one of four priority therapeutic areas: cardiovascular; orthopaedics; emergency medicine/trauma; or ophthalmology.
The fund forms part of the Medical Research Future Fund, to help eligible organisations progress medical technologies and devices through to proof of concept: the point where they are attractive to secure further venture capital or other funding. BMTH2.0 is a fully funded grant programme that encourages, but does not require, matched funding to be provided by the applicant.
The allocation of grants is overseen by a committee managed by MTPConnect and includes AusBiotech, the MTAA and the Department of Health.
The programme is intended to address gaps in early biomedical and medical technology product development, and to increase the number of viable new health technologies for commercialisation. Grant opportunities will cover the entire research pipeline from basic to applied research, with a focus on the translation and commercialisation of discoveries.
Applications to BMTH2.0 will go through a two-stage process. Stage one’s eligible non-confidential EOIs will be reviewed by an independent selection panel of research, industry and investment experts. EOIs close on 15 July 2019.
Read more here.